ResearcherShanxi Medical UniversityNo recent work listed

Xiaowen Tian

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 9 November 2026

Matched on OpenAlex author ID A5062557314. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2022: 2 papers

Papers 2

Circ_0008768 Suppresses the Pancreatic Cancer Progression via miR-330- 3p/PTEN Axis. Last author DOI 10.2174/0929866529666220726144619 ↗
FGD5‑AS1 is an oncogenic lncRNA in pancreatic cancer and regulates the Wnt/β‑catenin signaling pathway via miR‑577. Co-author DOI 10.3892/or.2021.8232 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Yingkai Wang · 1 shared paper, 2022 · strength 0.20
- Paper Circ_0008768 Suppresses the Pancreatic Cancer Progression via miR-330- 3p/PTEN Axis. DOI 10.2174/0929866529666220726144619 ↗
Wenji Yan · 1 shared paper, 2022 · strength 0.16
- Paper FGD5‑AS1 is an oncogenic lncRNA in pancreatic cancer and regulates the Wnt/β‑catenin signaling pathway via miR‑577. DOI 10.3892/or.2021.8232 ↗
Weitao Zhang · 1 shared paper, 2022 · strength 0.16
- Paper FGD5‑AS1 is an oncogenic lncRNA in pancreatic cancer and regulates the Wnt/β‑catenin signaling pathway via miR‑577. DOI 10.3892/or.2021.8232 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.